Product Life Cycle Management Key To Sustaining Revenue Growth In European Gastroenterology Therapeutics Market

Main Category: GastroIntestinal / Gastroenterology
Article Date: 26 Nov 2007 - 8:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

The European gastroenterology therapeutics market is in the maturity phase and is highly competitive. Brand recognition and product efficacy drive product acceptance in the market. Downward price pressures caused by cost control measures adopted by European governments and the extensive availability of generics are negatively affecting overall revenue growth. Efficient life cycle management and product innovation will be key to sustaining market expansion.

Frost & Sullivan (http://www.pharma.frost.com) finds that the European Gastroenterology Therapeutics Market was valued at $10.64 billion in 2006 and estimates this to reach $11.74 billion in 2013.

If you are interested in a virtual brochure, which provides manufacturers, end users, and other industry participants with an overview of the investment analysis and growth opportunities in the European Gastroenterology Therapeutics Market, then send an e-mail to Radhika Menon Theodore, Corporate Communications, at rmtheodore@frost.com, with your full name, company name, title, telephone number, fax number, and e-mail address. Upon receipt of the above information, an overview will be sent to you by e-mail.

"The gastroenterology therapeutics market in Europe is driven principally by the proton pump inhibitors (PPI) segment," notes Frost & Sullivan Research Analyst John Paul. "Poor lifestyles continue to promote the uptake of gastroenterology therapies, and PPI, with its superior efficacy, will help maintain revenue growth."

PPIs are replacing the less effective Histamine-2 receptor antagonists and antacids as the primary choice for treating gastroesophageal reflux and peptic ulcer diseases. The lack of innovative therapies in the pipeline implies the continued dominance of PPIs in the market.

Price control regulations implemented by European governments are severely affecting the revenues of market participants. Companies are being forced to reduce the price of their branded products to compete in the market, where generics are heavily recommended.

"The existing products in the market have little differentiation and do not cure the cause of the diseases," explains Paul. "Reference pricing policies implemented by governments are exerting downward pressures on the prices of branded PPIs because of the extensive availability of generic equivalents. Producing innovative products to treat the causes of the diseases is the only solution to prevent decreasing revenues."

The inflammatory bowel diseases market is a potential target for incumbent and prospective competitors. Patent protection and the expansion of the patient base through reformulation and approval of existing drugs for untargeted disease segments will be vital in the gastroesophageal reflux and peptic ulcer diseases markets. While anti-inflammatory agents and immunosuppressive agents provide relief for patients with inflammatory diseases, questionable side-effect profiles will stimulate the need for improved therapies.

European Gastroenterology Therapeutics Market is part of the Pharmaceutical & Biotechnology Growth Partnership Service Programme, which also includes research in the following markets: European bladder cancer therapeutics market, European prostrate cancer therapeutics market, European head and neck cancer therapeutics market and European testosterone replacement therapies market. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants. Interviews with the press are available.

Frost & Sullivan, the Growth Consulting Company, partners with clients to accelerate their growth. The company's Growth Partnership Services, Growth Consulting and Career Best Practices empower clients to create a growth focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents.

http://www.frost.com